Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reports Delayed Filing of Annual ReportApril 15, 2024

Emmaus reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

Emmaus Life Sciences Receives Marketing Authorization for Puerto RicoFebruary 02, 2024

Emmaus Life Sciences, Inc. today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder).

Emmaus Life Sciences Reports Q3 2023 Financial ResultsNovember 14, 2023

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.

Emmaus Life Sciences Reports Management ChangesAugust 23, 2023

Emmaus today reported that on August 18, 2023, the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board.

Emmaus Life Sciences Reports Q2 2023 Financial ResultsAugust 14, 2023

Emmaus Life Sciences, Inc. today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.